Health & Environmental Research Online (HERO)


Print Feedback Export to File
7417770 
Journal Article 
External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies 
Kurth, J; Krause, BJ; Schwarzenböck, SM; Stegger, L; Schäfers, M; Rahbar, K; , 
2018 
Prostate-specific membrane antigen (PSMA)-targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified.